title: The effect of the apolipoprotein E phenotype on cholesteryl ester transfer protein activity, plasma lipids and apolipoprotein A I levels in hypercholesterolaemic patients on colestipol and lovastatin treatment.
abstract: BACKGROUND
  Apolipoprotein E (apo E) allele E 4 is associated with high atherogenic lipid levels and coronary heart disease. Cholesteryl ester transfer protein (CETP) transfers cholesteryl esters from (high density lipoprotein) HDL to other lipoproteins. CETP gene expression is enhanced in hypercholesterolaemia and correlates with plasma apo E concentration.
  
  
  OBJECTIVE
  The effect of the apo E phenotype on plasma CETP activity and the hypolipidaemic efficacy of colestipol and lovastatin was studied in patients with type II a or II b hypercholesterolaemia.
  
  
  RESULTS
  The baseline mean plasma total, low density lipoprotein (LDL) and HDL cholesterol, triglyceride, apolipoprotein A I (apo A I) concentrations and CETP activity were 8.89 mmol x l(-1), 6.78 mmol x l(-1), 1.39 mmol x l(-1), 1.59 mmol x l(-1), 1.49 g x l(-1) and 114 nmol x h(-1) x ml(-1), respectively. The colestipol-induced changes were -26%, -36%, +5%, + 12%, -1% and -17%, and the lovastatin-induced changes -34%, -44%, +6%, -18%, +1% and -19%. The lipid and apo A I concentrations or the CETP activity did not differ statistically significantly according to the apo E phenotype, although the HDL cholesterol and apo A I levels were lowered in patients with apo E 4/4 but elevated in patients with the other phenotypes. The CETP activity correlated with the LDL cholesterol concentration (r = 0.52, P = 0.01) and the change in the LDL cholesterol during colestipol (r = 0.51, P = 0.02) and lovastatin (r = 0.65, P = 0.001) treatment, but only in patients without the apo E 4 allele.
  
  
  CONCLUSIONS
  Colestipol and lovastatin reduced CETP activity to the same amount, regardless of the apo E phenotype. The apo E phenotype seems to modify the interaction between CETP activity and LDL cholesterol in hypercholesterolaemia and during pharmacological lowering of cholesterol.
authors: Department of Internal Medicine, University of Oulu, Finland.
authors: T
authors: T
authors: Korhonen
authors: M L
authors: ML
authors: Hannuksela
authors: S
authors: S
authors: Seppänen
authors: K
authors: K
authors: Kervinen
authors: Y A
authors: YA
authors: Kesäniemi
authors: M J
authors: MJ
authors: Savolainen
mesh_terms: D000328:Adult; D001057:Apolipoproteins E / Q000235:genetics*; D002352:Carrier Proteins / Q000378:metabolism*; D002784:Cholesterol / Q000097:blood / Q000378:metabolism; D053480:Cholesterol Ester Transfer Proteins; D003084:Colestipol / Q000378:metabolism / Q000627:therapeutic use*; D005260:Female; D006023:Glycoproteins; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy* / Q000378:metabolism; D000960:Hypolipidemic Agents / Q000378:metabolism / Q000627:therapeutic use*; D008148:Lovastatin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D014280:Triglycerides / Q000097:blood
chemical_list: D001057:Apolipoproteins E; C506642:CETP protein, human; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D006023:Glycoproteins; D000960:Hypolipidemic Agents; D014280:Triglycerides; D002784:Cholesterol; D008148:Lovastatin; D003084:Colestipol